
Yahoo · 30 de oct de 2026
Pfizer's dividend yield sits near 6%, but the company paid out more in dividends last year than it generated in free cash flow. Before income investors panic or…
PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Últimos 252 días · 20/10/25 — 29/10/26
+26.89%
Precio
$ 12.670
Var. %
+2,67%
Volumen operado
468.926
Precio PFE
US$ 30,48
Teórico (precio / ratio)
PFE ÷ 4
US$ 7,62
Yield y fechas del subyacente vía Yahoo Finance. Ver calendario de dividendos.
Yield (USD)
5,7 %
Frecuencia (estimada)
Trim.
Próxima ex-date
05/11
Próximo pago
06/12
Cobro estimado (anual)
Dividendo anual USD ÷ ratio 4
USD 0,43
Sí, existe el CEDEAR de PFE (Pfizer Inc.) en la Bolsa de Comercio de Buenos Aires (BYMA). Su ticker local es PFE.
El ticker del CEDEAR de Pfizer Inc. en Argentina es PFE. La acción subyacente cotiza en NYSE con el símbolo PFE.
El CEDEAR PFE tiene un ratio de 4:1. Eso significa que 4 CEDEARs equivalen a 1 acción de PFE.
El CEDEAR PFE cotiza hoy a $ 12.670 en pesos argentinos, con una variación diaria de +2,67%.
Otros CEDEARs de Salud.

Yahoo · 30 de oct de 2026
Pfizer's dividend yield sits near 6%, but the company paid out more in dividends last year than it generated in free cash flow. Before income investors panic or…

Yahoo · 30 de oct de 2026
Halozyme is poised for a Q3 earnings beat as strong demand for partnered drugs is likely to boost royalties and drive the top line.

Yahoo · 30 de oct de 2026
For questions about this article or underlying research, email help@trefis.com.
Precio de cierre en pesos argentinos. Fuente: data912.
Cotización
US$ 8,13
vs teórico
+6,69%
Cotización MEP implícita
$ 1.558,43
Cotización
US$ 7,64
vs teórico
+0,26%
Cotización Cable implícita
$ 1.658,38
La acción subyacente PFE (Pfizer Inc.) cotiza a US$ 30,48 en su mercado de origen (NYSE).
El precio teórico del CEDEAR PFE se calcula dividiendo el precio de PFE por el ratio (4). Hoy resulta en US$ 7,62.
En BYMA podés operar PFE en pesos, PFED en dólar MEP y PFEC en dólar cable. Cada modalidad refleja un tipo de cambio distinto.
En esta página encontrás un gráfico con el precio histórico del CEDEAR PFE en pesos argentinos, con datos de data912.

SeekingAlpha · 30 de oct de 2026
Pfizer is downgraded from Buy to Hold as analyst sentiment turns increasingly bearish and growth prospects dim. Read more on PFE stock here.

Yahoo · 30 de oct de 2026
For questions about this article or underlying research, email help@trefis.com.

Yahoo · 30 de oct de 2026
Pfizer reported that its Phase 3 MagnetisMM-32 trial of ELREXFIO met the primary endpoint in relapsed or refractory multiple myeloma, while the FDA expanded app…

Yahoo · 29 de oct de 2026
For questions about this article or underlying research, email help@trefis.com.
Benzinga · 29 de oct de 2026
https://www.sec.gov/ix?doc=/Archives/edgar/data/1177648/000119312526437774/enta-20261029.htm
Noticias vía Finnhub